These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25075421)

  • 41. Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation.
    Neumann M; Klar S; Wilisch-Neumann A; Hollenbach E; Kavuri S; Leverkus M; Kandolf R; Brunner-Weinzierl MC; Klingel K
    Oncogene; 2011 May; 30(21):2485-92. PubMed ID: 21217772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cleavage of GSK-3β by calpain counteracts the inhibitory effect of Ser9 phosphorylation on GSK-3β activity induced by H₂O₂.
    Feng Y; Xia Y; Yu G; Shu X; Ge H; Zeng K; Wang J; Wang X
    J Neurochem; 2013 Jul; 126(2):234-42. PubMed ID: 23646926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta.
    Silva R; Mesquita AR; Bessa J; Sousa JC; Sotiropoulos I; Leão P; Almeida OF; Sousa N
    Neuroscience; 2008 Mar; 152(3):656-69. PubMed ID: 18291594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycogen synthase kinase-3β does not correlate with the expression and activity of β-catenin in gastric cancer.
    Cho YJ; Yoon J; Ko YS; Kim SY; Cho SJ; Kim WH; Park JW; Youn HD; Kim JH; Lee BL
    APMIS; 2010 Oct; 118(10):782-90. PubMed ID: 20854473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The relationship between the Wnt signaling and the psychiatric diseases].
    Ferrero A; Cereseto M; Sifonios L
    Vertex; 2006; 17(67):165-71. PubMed ID: 16847474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is glycogen synthase kinase-3 a central modulator in mood regulation?
    Li X; Jope RS
    Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. No association of GSK3beta gene (GSK3B) with Japanese schizophrenia.
    Ikeda M; Iwata N; Suzuki T; Kitajima T; Yamanouchi Y; Kinoshita Y; Ozaki N
    Am J Med Genet B Neuropsychiatr Genet; 2005 Apr; 134B(1):90-2. PubMed ID: 15719395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuronal signaling pathways: genetic insights into the pathophysiology of major mental illness.
    Margolis RL; Ross CA
    Neuropsychopharmacology; 2010 Jan; 35(1):350-1. PubMed ID: 20010716
    [No Abstract]   [Full Text] [Related]  

  • 49. In this correspondence, preliminary data in 100 lithium users found that urine osmolality correlated with chronic kidney disease, diabetes mellitus, and hypothyroidism. We hypothesize that GSK-3β inhibition is a potential mechanism for lithium-associated medical illness.
    Rej S; Segal M; Low NC; Mucsi I; Holcroft C; Shulman K; Looper KJ
    Med Hypotheses; 2015 Jun; 84(6):602. PubMed ID: 25777472
    [No Abstract]   [Full Text] [Related]  

  • 50. Implication of the polyamine system in mental disorders.
    Fiori LM; Turecki G
    J Psychiatry Neurosci; 2008 Mar; 33(2):102-10. PubMed ID: 18330456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Looking ahead: electroretinographic anomalies, glycogen synthase kinase-3, and biomarkers for neuropsychiatric disorders.
    Chen G; Henter ID; Manji HK
    Biol Psychiatry; 2014 Jul; 76(2):86-8. PubMed ID: 24948381
    [No Abstract]   [Full Text] [Related]  

  • 52. Proceedings of the International Meeting on Japanese Psychopharmacology Algorithms. Yokohama, Japan, 23 April 1998. Proposals for the rational selections of drugs in the treatment of schizophrenia and mood disorders.
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S1-82. PubMed ID: 10610193
    [No Abstract]   [Full Text] [Related]  

  • 53. [The relationship between glycogen synthase kinase-3 beta (GSK3B) -50T/C -1727A/T polymorphisms and alcoholism].
    Yoshihara E; Aoki J; Kurihara K; Numajiri M; Iwahashi K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2011 Dec; 46(6):570-5. PubMed ID: 22413565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DISC1: a schizophrenia gene with multiple personalities.
    Wexler EM; Geschwind DH
    Neuron; 2011 Nov; 72(4):501-3. PubMed ID: 22099453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders.
    Beurel E
    Neuroimmunomodulation; 2014; 21(2-3):140-4. PubMed ID: 24557047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Looking beyond the role of glycogen synthase kinase-3 genetic expression on electroretinogram response: what about lithium?
    Lavoie J; Hébert M; Beaulieu JM
    Biol Psychiatry; 2015 Feb; 77(3):e15-e17. PubMed ID: 25193244
    [No Abstract]   [Full Text] [Related]  

  • 57. The action of mood-stabilizers in affective disorders: an integrative view as a challenge.
    Emrich HM; Dose M; Wolf R
    Neuropsychobiology; 1993; 27(3):158-62. PubMed ID: 8232832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Schizophrenia: A point of disruption.
    Ross CA; Margolis RL
    Nature; 2009 Apr; 458(7241):976-7. PubMed ID: 19396131
    [No Abstract]   [Full Text] [Related]  

  • 59. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition?
    Stahl SM
    J Clin Psychiatry; 2008 Nov; 69(11):1673-4. PubMed ID: 19200426
    [No Abstract]   [Full Text] [Related]  

  • 60. Intracellular signalling pathways and mood disorders.
    Fišar Z; Hroudová J
    Folia Biol (Praha); 2010; 56(4):135-48. PubMed ID: 20974046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.